# A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06253130/  
OnCo record `nct06253130` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This study tests a PARP inhibitor; the registry reports that it is recruiting.

## Summary

The registry lists NCT06253130 as recruiting, last updated 2026-06-15. Enrolment is 156 planned participants, an estimate. Interventions: IMP1734. Primary measures include Number of subjects with adverse events, treatment emergent adverse events or serious adverse events; Maxim Tolerated Dose or Recommended Dose for Expansion. No results are posted in the registry; this does not exclude separate publications.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06253130
- Phase: 1/2
- Setting: A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors
- Sponsor: Eikon Therapeutics

## Sources

- ClinicalTrials.gov NCT06253130: https://clinicaltrials.gov/study/NCT06253130

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [PARP](https://onco.cc/targets/parp/)
- drugs: [IMP1734](https://onco.cc/drugs/imp1734/)
- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/), [IMPACT Therapeutics](https://onco.cc/companies/impact-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct06253130.json